Oncomed Pharmaceuticals (OMED) Receiving Somewhat Favorable News Coverage, Study Finds
Media stories about Oncomed Pharmaceuticals (NASDAQ:OMED) have trended somewhat positive on Friday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 48.5551082779967 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
OMED has been the topic of a number of recent analyst reports. ValuEngine raised shares of Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research lowered shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 17th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Oncomed Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $4.30.
OMED stock traded up $0.02 during mid-day trading on Friday, hitting $2.48. The company had a trading volume of 11,000 shares, compared to its average volume of 138,594. The firm has a market cap of $93.17 million, a price-to-earnings ratio of -2.38 and a beta of 1.78. Oncomed Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $5.56.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.